Dynavax and Clover Biopharmaceuticals Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with CpG 1018 Adjuvant

  • Dynavax is providing CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, to support the rapid development of Clover’s COVID-19 vaccine
  • Clover advancing evaluation of its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer)

EMERYVILLE, Calif. and CHENGDU, China, March 24, …